PAM
NKTR icon

Private Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Private Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,377
Closed -$279K – 151
2021
Q4 		$279K Buy
1,377
+495
+56% +$107K 0.03% 135
2021
Q3 		$238K Sell
882
-1,795
-67% -$432K 0.03% 139
2021
Q2 		$689K Sell
2,677
-23
-0.9% -$6.37K 0.09% 97
2021
Q1 		$810K Buy
2,700
+213
+9% +$66.3K 0.11% 86
2020
Q4 		$634K Buy
2,487
+17
+0.7% +$4.39K 0.1% 90
2020
Q3 		$615K Buy
2,470
+55
+2% +$17.3K 0.1% 87
2020
Q2 		$839K Buy
2,415
+430
+22% +$134K 0.15% 79
2020
Q1 		$532K Buy
1,985
+678
+52% +$210K 0.11% 82
2019
Q4 		$423K Buy
+1,307
New +$379K 0.07% 99

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Private Asset Management's NKTR Position: Q1 2022 in Review

Private Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 1,377 shares — an estimated $279K sold.

Private Asset Management first reported a position in NKTR in Q4 2019 and held it in 9 quarters. The position peaked at $839K in Q2 2020. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • Private Asset Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Private Asset Management sold 1,377 Nektar Therapeutics shares in Q1 2022, an estimated $279K.
  • Private Asset Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 9 quarters.
  • Private Asset Management's Nektar Therapeutics position peaked at $839K in Q2 2020.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Private Asset Management's 13F filing for Q1 2022, filed 4 Apr 2022.